Aadi Bioscience (AADI)
(Real Time Quote from BATS)
$1.90 USD
+0.06 (3.26%)
Updated Sep 18, 2024 02:20 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Aadi Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 24 | 15 | 1 | 15 | 0 |
Cost Of Goods | 3 | 1 | 0 | 0 | 0 |
Gross Profit | 22 | 14 | 1 | 15 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 93 | 77 | 112 | 21 | 24 |
Income After Depreciation & Amortization | -72 | -63 | -111 | -6 | -24 |
Non-Operating Income | 6 | 2 | 2 | 2 | 1 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | -66 | -61 | -110 | -4 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -66 | -61 | -110 | -4 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -66 | -61 | -110 | -4 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -60 | -37 | -6 | -24 |
Depreciation & Amortization (Cash Flow) | -3 | 3 | 74 | 0 | 0 |
Income After Depreciation & Amortization | -72 | -63 | -111 | -6 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.92 | 22.51 | 8.92 | 2.84 | 2.71 |
Diluted EPS Before Non-Recurring Items | -2.44 | -2.56 | -4.12 | -1.50 | -7.95 |
Diluted Net EPS (GAAP) | -2.44 | -2.69 | -12.41 | -1.50 | -8.55 |
Fiscal Year end for Aadi Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 6.18 | 5.35 | 6.33 | 5.96 | 6.20 |
Cost Of Goods | 0.78 | 0.65 | 0.93 | 0.70 | 0.66 |
Gross Profit | 5.40 | 4.70 | 5.40 | 5.26 | 5.55 |
SG&A, R&D, and Dept/Amort Expenses | 20.98 | 24.21 | 23.12 | 23.11 | 25.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.58 | -19.51 | -17.72 | -17.85 | -19.55 |
Non-Operating Income | 1.06 | 1.28 | 1.50 | 1.61 | 1.63 |
Interest Expense | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Pretax Income | -14.58 | -18.29 | -16.27 | -16.30 | -17.97 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -14.58 | -18.29 | -16.27 | -16.30 | -17.97 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -14.58 | -18.29 | -16.27 | -16.30 | -17.97 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 27.01 | 26.98 | 26.97 | 26.95 | 26.88 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.68 | -0.60 | -0.60 | -0.67 |
Diluted Net EPS (GAAP) | -0.54 | -0.68 | -0.60 | -0.60 | -0.67 |